ArticleJournal of fluorescence2025
Current Practices and Perceptions of Indocyanine Green Fluorescence Guided Liver Surgery: Insights from a Survey of Hepato-Pancreato-Biliary Surgeons in the United Kingdom.
Article in Journal of fluorescence, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Indocyanine Green (ICG) fluorescence-guided surgery (I-FIGS) is increasingly being used in hepato-pancreatico-biliary (HPB) surgery. However, the true benefit of I-FIGS, the optimum dosing, and the timing of ICG administration still need to be determined. To conduct future research studies in the above areas, it is essential to understand the current I-FIGS practices among surgeons. This survey investigated the practices and perceptions of I-FIGS in liver surgery among HPB surgeons in the United Kingdom (UK). A survey was sent via email and social media to surgeons from all HPB units in the UK. The survey consisted of 18 questions, covering various aspects such as experience levels, volume of operations, approach to liver resections, ICG dosage, timing of administration, application specifics, camera systems used, and willingness to participate in future trials. The survey was sent to 81 HPB surgeons (working in 25 HPB units) across the UK. The response rate was 70% (57/81 surgeons). 56% of the surgeons reported having the infrastructure for I-FIGS at their hospital. The use of I-FIGS varied in duration and patient volume, with 47% of surgeons reporting its use for less than one year and 53% of surgeons reporting using it in fewer than ten patients. Preferences for the dose and timing of ICG administration also varied, reflecting the absence of standardised guidelines. The Storz camera system emerged as the most used imaging system (42% of surgeons), followed by the Stryker (25.8%). None of the surgeons reported any I-FIGS-related side effects. Ninety-six per cent of surgeons expressed interest in participating in future clinical trials in the field of I-FIGS. The survey highlights that I-FIGS in liver surgery is not widely used in the UK. There are also wide variations in the dosing and timing of ICG administration. Large multi-centre studies are needed to focus on dosing, timing of ICG administration, and establishing its actual role in liver surgery.
Indexed as
Identifiers
39644369What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.